Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576773 | 0.83 | CYP2D6 (0.71) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 | |
| SCHEMBL14679114 | 0.81 | CYP2D6 (0.73) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 | |
| SCHEMBL27896059 | 0.80 | CYP2D6 (0.55) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 | |
| SCHEMBL15153463 | 0.80 | CYP2D6 (0.71) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 | |
| SCHEMBL1258725 | 0.80 | CYP2D6 (0.67) | CYP2D6GAAKMT2ALMNAHTT | |
| SCHEMBL2989541 | 0.80 | CYP2D6 (0.67) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 | |
| SCHEMBL5198652 | 0.78 | KMT2A (0.60) | CYP2D6KMT2ALMNAMAPK1CA12 | |
| SCHEMBL8127203 | 0.75 | HDAC2 (0.72) | CYP2D6HDAC8HDAC6CYP2C9GAA | |
| SCHEMBL2222201 | 0.74 | CARM1 (0.51) | HDAC6CYP2C19KMT2ALMNA | |
| SCHEMBL744542 | 0.74 | POLB (0.64) | CYP2D6CYP2C19KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | claimed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | claimed |
| EP-2150539-B1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-07-15 | — | — | US | disclosed |
| EP-2150539-A1 | PYRIDAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008145243-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, RET | CYP2D6 562/4885HDAC8 3161/4885HDAC6 3507/4885 |
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | CYP2D6 214/4885HDAC8 578/4885HDAC6 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.